SOT102: Claudin 18.2 Targeting PNU-based ADC for the Treatment of Gastric & Pancreatic Cancer

Time: 4:45 pm
day: Day One


  • Differentiated ADC targeting CLDN18.2 with novel proprietary antibody
  • Built on NBE Therapeutics iADC platform: PNU toxin, sortase-mediated coupling
  • Recruitment of the Phase I trial to start in March 2022